What is the official website of Novartis Science ?

The official website of Novartis Science is https://www.novartis.com/research-development.

What is Novartis Science's cybersecurity risk score?

Novartis Science has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Science experienced?

According to Rankiteo, Novartis Science currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Science been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Science has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Science have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Science is not certified under SOC 2 Type 1.

Does Novartis Science have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Science does not hold a SOC 2 Type 2 certification.

Does Novartis Science comply with GDPR ?

According to Rankiteo, Novartis Science is not listed as GDPR compliant.

Does Novartis Science have PCI DSS certification ?

According to Rankiteo, Novartis Science does not currently maintain PCI DSS compliance.

Does Novartis Science comply with HIPAA ?

According to Rankiteo, Novartis Science is not compliant with HIPAA regulations.

Does Novartis Science have ISO 27001 certification ?

According to Rankiteo,Novartis Science is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Science operate in ?

Novartis Science operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Science have ?

Novartis Science employs approximately 18 people worldwide.

Does Novartis Science own any subsidiaries ?

Novartis Science presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Science have ?

Novartis Science's official LinkedIn profile has approximately 220,678 followers.

What is the NAICS classification code for Novartis Science ?

Novartis Science is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Science have a Crunchbase profile ?

No, Novartis Science does not have a profile on Crunchbase.

Does Novartis Science have a LinkedIn profile ?

Yes, Novartis Science maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-science.

How many cybersecurity incidents has Novartis Science experienced ?

As of June 20, 2026, Rankiteo reports that Novartis Science has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Science have ?

Novartis Science has an estimated 5,693 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Science faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Science

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Science Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is an innovative medicines company with research and development at its core. Our R&D engine powers an industry-leading pipeline dedicated to delivering transformative medicines to fight disease, restore possibilities and help people live life on their own terms. See our community guidelines: https://go.novartis.social/4bqbjuA

Novartis Science A.I CyberSecurity Scoring

Scoring History

Novartis Science

Novartis Science CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Science

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Science Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Science

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Science in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Science in 2026.

Incident Types Novartis Science vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Science in 2026.

Incident History - Novartis Science (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Science Subsidiaries

Novartis Science

Pharmaceutical Manufacturing

Website: https://www.novartis.com/research-development

Company Size: 18

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Loading…

Novartis Science Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Loading…

NEWS

Novartis Science CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

February 08, 2026 08:00 AM

Your money online is at risk: UAE’s Cyber Security Council issues warning

The council stressed that steps taken to safeguard personal and financial data across cyberspace reduces the risk of falling victim to cyber...

Read Article

December 17, 2025 08:00 AM

Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally

SAN FRANCISCO, December 17, 2025--Salesforce (NYSE: CRM), the world's #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global...

Read Article

May 20, 2025 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

March 03, 2025 08:00 AM

February M&A deals: Thermo Fisher, Novartis, and CyberArk Software

Thermo Fisher Scientific Inc. struck a deal with Minnesota-based health care company, Solventum, to buy its purification and filtration business for about $4.1...

Read Article

February 16, 2025 08:00 AM

Ranking the Top 10 High-Paying Tech Jobs in Switzerland in 2025

Explore the top 10 high-paying tech jobs in Switzerland for 2025, including AI, cybersecurity, and cloud computing roles, offering lucrative...

Read Article

December 23, 2024 08:00 AM

Ranking the Top 10 High-Paying Tech Jobs in Switzerland

The Swiss tech industry is thriving, with high demand for roles like Chief Information Officer, Cloud Solutions Architect,...

Read Article

December 23, 2024 08:00 AM

Top 10 Tech Internships Offered in Switzerland

Discover the top 10 tech internships in Switzerland, from Google to Novartis. Learn about opportunities, application tips, and benefits for...

Read Article

October 17, 2024 07:00 AM

Brave new world: Building Europe’s capacities for defence and security R&D

For the first time since the end of the Cold War, the next period of EU politics and policy-making will be dominated by security issues.

Read Article

July 19, 2024 07:00 AM

Pharma companies report various levels of exposure to IT outage caused by CrowdStrike, Microsoft

While the international IT outage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56082

SUMMARY

Capgo (Cap-go/capgo) before 12.128.2 contains an improper access control vulnerability in the SECURITY DEFINER PostgREST RPC function public.record_build_time, which is granted to the anon role and callable with only the public Supabase publishable (sb_publishable_*) anon key. An unauthenticated attacker can insert rows into public.build_logs for arbitrary organizations and, because the function uses ON CONFLICT (build_id, org_id) DO UPDATE, can overwrite existing usage/billing records by reusing the same build_id for a target org. This enables cross-tenant tampering of billing build logs and financial-impact denial of service by inflating billable build time.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56081

SUMMARY

Cap-go before 12.128.2 contains an authentication logic flaw that lets an attacker register and control an account bound to a victim's email address before that email is verified. By enabling two-factor authentication on the pre-registered account, the attacker gains control over the account claimed under the victim's identity, allowing them to read and modify its state and enforce organization-level policies, while the legitimate user is denied access to the account tied to their own email.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-56080

SUMMARY

Capgo before 12.128.2 contains a flaw in the Enforce Password Policy feature: after a Super Admin enables the policy and successfully changes their password to a compliant one, the backend does not update the password-compliance state. As a result, the backend continues to treat the account as non-compliant and repeatedly forces password-reset prompts, permanently locking the Super Admin out of organization access (organization lockout / denial of service) despite valid authentication.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 4.9)

cvss3

Base Score: 4.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.2

REFERENCES

CVE-2026-56079

SUMMARY

Capgo before 12.128.2 contains a cross-tenant authorization bypass vulnerability in PostgREST endpoints that allows org-scoped read API keys to access other tenants' webhook secrets and delivery logs. Attackers can query the webhooks and webhook_deliveries endpoints to exfiltrate HMAC signing secrets and delivery payloads, enabling forged webhook events against victim organizations.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-56073

SUMMARY

Cap-go before 12.128.2 contains an authentication bypass vulnerability in OTP verification that allows attackers to bypass email verification by modifying server responses. Attackers can intercept OTP verification requests and manipulate HTTP responses to falsely mark verification successful, enabling unauthorized 2FA enablement and account takeover.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.4)

cvss3

Base Score: 9.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:L

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.5

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…